Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study
Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment rand...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 1990, Vol.13, p.S92-S99 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S99 |
|---|---|
| container_issue | |
| container_start_page | S92 |
| container_title | Clinical neuropharmacology |
| container_volume | 13 |
| creator | CARBONIN, P.-U GRECO, A PISANTI, P GEMMA, A CATTELIN, F |
| description | Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001). |
| doi_str_mv | 10.1097/00002826-199013003-00010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80338657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80338657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-6dc34759fc077a3fb0ad8416d5dd6a5b491eaaba73eab99c0e29fbb8e14b86903</originalsourceid><addsrcrecordid>eNpFUctuFDEQtBBRWAKfgOQLnGLi13jG3FCUAFIkLiBxG7Vfi5HHXuwZpP0A_huTLKEv3eqqrpK6EMKMvmVUj1e0F5-4IkxrygSlgvQNo0_Qjg1iJEzxb0_RjgrFyaCUfIaet_ajUyYt9Tk651QLyfkO_b4JIVqwR1wChrTEtcbsSYXNQOsTjhnbss9xjb88drGV6nxt9-x9zHv8DgN2ZTPJE5Nidpf4kMB6U4gtea0lJd93tkPdJmHIDh_a0X4vi-9WFrd1c8cX6CxAav7lqV-gr7c3X64_krvPHz5dv78jlk_DSpSzQo6DDpaOI4hgKLhJMuUG5xQMRmrmAQyMwoPR2lLPdTBm8kyaSWkqLtCbB91DLT8339Z5ic36lCD7srV5okJMahg7cXog2lpaqz7MhxoXqMeZ0flvAvO_BObHBOb7BPrpq5PHZhbvHg9PL-_46xMOrX8kVMg2tv_6epBSUin-AB-BkNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80338657</pqid></control><display><type>article</type><title>Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>CARBONIN, P.-U ; GRECO, A ; PISANTI, P ; GEMMA, A ; CATTELIN, F</creator><creatorcontrib>CARBONIN, P.-U ; GRECO, A ; PISANTI, P ; GEMMA, A ; CATTELIN, F</creatorcontrib><description>Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001).</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/00002826-199013003-00010</identifier><identifier>PMID: 2093422</identifier><identifier>CODEN: CLNEDB</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Aged ; Aged, 80 and over ; Aging - psychology ; Almitrine - therapeutic use ; Biological and medical sciences ; Cognition Disorders - drug therapy ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychological Tests ; Psychology. Psychoanalysis. Psychiatry ; Psychometrics ; Psychopharmacology ; Secologanin Tryptamine Alkaloids ; Yohimbine - analogs & derivatives ; Yohimbine - therapeutic use</subject><ispartof>Clinical neuropharmacology, 1990, Vol.13, p.S92-S99</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,4010,4036,4037,23909,23910,25118,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19544404$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2093422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CARBONIN, P.-U</creatorcontrib><creatorcontrib>GRECO, A</creatorcontrib><creatorcontrib>PISANTI, P</creatorcontrib><creatorcontrib>GEMMA, A</creatorcontrib><creatorcontrib>CATTELIN, F</creatorcontrib><title>Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001).</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aging - psychology</subject><subject>Almitrine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cognition Disorders - drug therapy</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychological Tests</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychometrics</subject><subject>Psychopharmacology</subject><subject>Secologanin Tryptamine Alkaloids</subject><subject>Yohimbine - analogs & derivatives</subject><subject>Yohimbine - therapeutic use</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUctuFDEQtBBRWAKfgOQLnGLi13jG3FCUAFIkLiBxG7Vfi5HHXuwZpP0A_huTLKEv3eqqrpK6EMKMvmVUj1e0F5-4IkxrygSlgvQNo0_Qjg1iJEzxb0_RjgrFyaCUfIaet_ajUyYt9Tk651QLyfkO_b4JIVqwR1wChrTEtcbsSYXNQOsTjhnbss9xjb88drGV6nxt9-x9zHv8DgN2ZTPJE5Nidpf4kMB6U4gtea0lJd93tkPdJmHIDh_a0X4vi-9WFrd1c8cX6CxAav7lqV-gr7c3X64_krvPHz5dv78jlk_DSpSzQo6DDpaOI4hgKLhJMuUG5xQMRmrmAQyMwoPR2lLPdTBm8kyaSWkqLtCbB91DLT8339Z5ic36lCD7srV5okJMahg7cXog2lpaqz7MhxoXqMeZ0flvAvO_BObHBOb7BPrpq5PHZhbvHg9PL-_46xMOrX8kVMg2tv_6epBSUin-AB-BkNw</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>CARBONIN, P.-U</creator><creator>GRECO, A</creator><creator>PISANTI, P</creator><creator>GEMMA, A</creator><creator>CATTELIN, F</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1990</creationdate><title>Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study</title><author>CARBONIN, P.-U ; GRECO, A ; PISANTI, P ; GEMMA, A ; CATTELIN, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-6dc34759fc077a3fb0ad8416d5dd6a5b491eaaba73eab99c0e29fbb8e14b86903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aging - psychology</topic><topic>Almitrine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cognition Disorders - drug therapy</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychological Tests</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychometrics</topic><topic>Psychopharmacology</topic><topic>Secologanin Tryptamine Alkaloids</topic><topic>Yohimbine - analogs & derivatives</topic><topic>Yohimbine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CARBONIN, P.-U</creatorcontrib><creatorcontrib>GRECO, A</creatorcontrib><creatorcontrib>PISANTI, P</creatorcontrib><creatorcontrib>GEMMA, A</creatorcontrib><creatorcontrib>CATTELIN, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CARBONIN, P.-U</au><au>GRECO, A</au><au>PISANTI, P</au><au>GEMMA, A</au><au>CATTELIN, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>1990</date><risdate>1990</risdate><volume>13</volume><spage>S92</spage><epage>S99</epage><pages>S92-S99</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><coden>CLNEDB</coden><abstract>Early treatment of age-related cognitive impairment can be decisive in enabling elderly patients to remain at home. A double-blind, placebo-controlled trial of almitrine-raubasine was conducted in 40 elderly outpatients (25 women, 15 men; mean age: 73.5 years) with moderate cognitive impairment randomized into two groups, one receiving almitrine and raubasine, the other placebo, two tablets daily for 90 days. They were assessed at T0, T45 and T90 days, using the Toulouse-Pieron test, 8 subtests from the Wechsler Adult Intelligence Scale (WAIS) and the Sandoz Clinical Assessment for Geriatrics (SCAG). End-of-study results were significantly better in the almitrine-raubasine group in all tests: Toulouse-Pieron test (p less than 0.001), WAIS (p less than 0.001), and SCAG (p less than 0.001).</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>2093422</pmid><doi>10.1097/00002826-199013003-00010</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 1990, Vol.13, p.S92-S99 |
| issn | 0362-5664 1537-162X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80338657 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Aged, 80 and over Aging - psychology Almitrine - therapeutic use Biological and medical sciences Cognition Disorders - drug therapy Double-Blind Method Drug Combinations Female Humans Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychological Tests Psychology. Psychoanalysis. Psychiatry Psychometrics Psychopharmacology Secologanin Tryptamine Alkaloids Yohimbine - analogs & derivatives Yohimbine - therapeutic use |
| title | Efficacy of almitrine-raubasine in cognitive disorders of aging : a double-blind, placebo-controlled, clinical and psychometric study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T10%3A18%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20almitrine-raubasine%20in%20cognitive%20disorders%20of%20aging%20:%20a%20double-blind,%20placebo-controlled,%20clinical%20and%20psychometric%20study&rft.jtitle=Clinical%20neuropharmacology&rft.au=CARBONIN,%20P.-U&rft.date=1990&rft.volume=13&rft.spage=S92&rft.epage=S99&rft.pages=S92-S99&rft.issn=0362-5664&rft.eissn=1537-162X&rft.coden=CLNEDB&rft_id=info:doi/10.1097/00002826-199013003-00010&rft_dat=%3Cproquest_cross%3E80338657%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80338657&rft_id=info:pmid/2093422&rfr_iscdi=true |